• 1. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 2. Alt-proteins: A promising future
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886

Research Brief on (1,2-dimethylpropyl)propylamine (CAS: 39190-94-8) in Chemical Biology and Pharmaceutical Applications

The compound (1,2-dimethylpropyl)propylamine (CAS: 39190-94-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and relevance in drug development. The following sections provide a comprehensive overview of the current state of research, highlighting key advancements and future directions.

Recent studies have explored the synthetic pathways for (1,2-dimethylpropyl)propylamine, emphasizing its role as a versatile intermediate in the production of more complex bioactive molecules. Researchers have optimized reaction conditions to improve yield and purity, leveraging advanced catalytic systems and green chemistry principles. These advancements are critical for scaling up production while minimizing environmental impact, aligning with the pharmaceutical industry's growing emphasis on sustainable practices.

In terms of biological activity, (1,2-dimethylpropyl)propylamine has demonstrated promising interactions with central nervous system (CNS) targets. Preliminary in vitro and in vivo studies suggest its potential as a modulator of neurotransmitter systems, particularly those involving dopamine and serotonin. These findings open avenues for further investigation into its applicability in treating neurological disorders such as depression, anxiety, and Parkinson's disease. However, detailed mechanistic studies and safety profiles are still required to validate these early observations.

Another area of interest is the compound's potential as a building block for novel drug candidates. Its structural features, including the branched alkyl chain and amine functionality, make it a valuable scaffold for medicinal chemistry. Researchers have reported its incorporation into larger pharmacophores, yielding derivatives with enhanced bioavailability and target specificity. Computational modeling and structure-activity relationship (SAR) studies have further elucidated the optimal modifications for maximizing therapeutic efficacy while minimizing off-target effects.

Despite these promising developments, challenges remain in the clinical translation of (1,2-dimethylpropyl)propylamine-based therapies. Issues such as metabolic stability, toxicity, and formulation compatibility need to be addressed through rigorous preclinical testing. Collaborative efforts between academia and industry will be essential to overcome these hurdles and accelerate the development of viable drug candidates. Additionally, regulatory considerations must be factored into the research pipeline to ensure compliance with global standards.

In conclusion, (1,2-dimethylpropyl)propylamine (CAS: 39190-94-8) represents a compelling subject of study in the intersection of chemical biology and pharmaceutical science. Its synthetic versatility, biological activity, and potential therapeutic applications underscore its importance in contemporary research. Future studies should focus on elucidating its mechanisms of action, optimizing its pharmacological properties, and advancing it through the drug development pipeline. This brief serves as a foundation for researchers seeking to explore the multifaceted roles of this compound in advancing human health.

• 2738-06-9(n-ethyl-1,2-dimethylpropylamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)